Saturday, July 5, 2025

Latest

Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright Minds Biosciences (NASDAQ: DRUG). The firm is focused on the development of second generation psychedelic pharmaceuticals for treatment of neuropsychiatric disorders, which will maintain IP protections, unlike its peers whom are largely focused on first generation psychedelic compounds.

As of the last quarter, the company had $22M cash on the balance sheet with only 12M shares outstanding. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs, with members of its scientific team including renowned scientists like Dr. Alan Kozikowski and Dr. Gideon Shapiro.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

Torex Gold Acquires Reyna Silver For CASH!

Dundee Acquires Adriatic Metals: The Balkan Growth Strategy

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This...

Wednesday, September 22, 2021, 03:24:00 PM

Bright Minds Expands Leadership, Scientific Advisory Teams

Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two...

Tuesday, April 27, 2021, 08:44:04 AM

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM

Bright Minds Applies For Nasdaq Listing

Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company...

Wednesday, June 16, 2021, 07:33:59 AM